MetLife Investment Management’s LCNB Corp LCNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$146K Buy
8,318
+1,867
+29% +$31.1K ﹤0.01% 2582
2026
Q1
$101K Hold
6,451
– – ﹤0.01% 2538
2025
Q4
$106K Hold
6,451
– – ﹤0.01% 2578
2025
Q3
$96.7K Sell
6,451
-3,027
-32% -$46.7K ﹤0.01% 2667
2025
Q2
$138K Buy
9,478
+3,146
+50% +$45.6K ﹤0.01% 2381
2025
Q1
$93.7K Hold
6,332
– – ﹤0.01% 2552
2024
Q4
$95.8K Hold
6,332
– – ﹤0.01% 2640
2024
Q3
$95.4K Hold
6,332
– – ﹤0.01% 2645
2024
Q2
$88.1K Buy
6,332
+595
+10% +$8.54K ﹤0.01% 2661
2024
Q1
$91.4K Hold
5,737
– – ﹤0.01% 2576
2023
Q4
$90.5K Hold
5,737
– – ﹤0.01% 2649
2023
Q3
$81.9K Hold
5,737
– – ﹤0.01% 2679
2023
Q2
$84.7K Buy
+5,737
New +$87.7K ﹤0.01% 2786
2020
Q2
– Sell
-6,097
Closed -$76.8K – 2327
2020
Q1
$76.8K Hold
6,097
– – ﹤0.01% 2189
2019
Q4
$118K Buy
+6,097
New +$111K ﹤0.01% 2242
2019
Q3
– Sell
-6,388
Closed -$121K – 2364
2019
Q2
$121K Buy
+6,388
New +$109K ﹤0.01% 2300

Other funds holding LCNB

MetLife Investment Management's LCNB Position: Q2 2026 in Review

MetLife Investment Management increased its LCNB Corp (LCNB) stake by 29% in Q2 2026, buying an estimated $31.1K and bringing the position to 8,318 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

MetLife Investment Management first reported a position in LCNB in Q2 2019 and has held it in 16 quarters since. 107 funds tracked by Wall St. Rank hold LCNB as of Q2 2026.

  • MetLife Investment Management held 8,318 shares of LCNB Corp worth $146K as of Q2 2026.
  • MetLife Investment Management bought 1,867 LCNB Corp shares in Q2 2026, an estimated $31.1K.
  • LCNB Corp made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2582 holding.
  • MetLife Investment Management first reported a position in LCNB Corp in Q2 2019 and has held it in 16 quarters since.
  • 107 funds tracked by Wall St. Rank held LCNB Corp as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.